224785-91-5

• 常用中文名：瓦地那非盐酸盐
• 常用英文名：Vardenafil
• CAS号：224785-91-5
• 分子式：C₂₃H₃₃ClN₆O₄S
• 分子量：525.064
• 相关类别： 信号通路 代谢酶/蛋白酶 磷酸二酯酶(PDE)
• 发布时间：2018-09-16 17:42:27
• 更新时间：2024-01-02 16:53:08
• Vardenafil盐酸盐是PDE5抑制剂。

名称

• 中文名: 瓦地拉非盐酸盐
• 英文名: Vardenafil hydrochloride
• 中文别名: 2-[2-乙氧基-5-(4-乙基哌嗪-1-基)磺酰苯基]-5-甲基-7-丙基-1H-咪唑并[5,1-f][1,2,4]三嗪-4-酮盐酸盐; VARDENAFIL盐酸盐; 伐地那非; 伐他那非盐酸盐
• 英文别名: VARDENAFIL,HYDROCHLORIDE SALT; Nuviva; Vivanza; Vardenafil HCl; Vardenafil (hydrochloride); Levitra,Valdenafil; 1-((3-(1,4-Dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethylpiperazine Hydrochloride; 2-{2-Ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-onhydrochlorid; 2-{2-Ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one hydrochloride (1:1); Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-, hydrochloride (1:1); piperazine, 1-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-, monohydrochloride; VARDENAFIL; VARDENAFILMONOHYDROCHLORIDE(SUBJECTTOPATENTFREE); Levitra; 4-{[4-ethoxy-3-(4-hydroxy-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)phenyl]sulfonyl}-1-ethylpiperazin-1-ium chloride; Levitra,Valdenafil.HCl; 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one hydrochloride; Vardenafil hydrochloride; 2-{2-éthoxy-5-[(4-éthylpipérazin-1-yl)sulfonyl]phényl}-5-méthyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one chlorhydrate

物化性质

• 沸点: 692.2ºC at 760 mmHg
• 熔点: 214-216ºC
• 分子式: C₂₃H₃₃ClN₆O₄S
• 分子量: 525.064
• 闪点: 372.5ºC
• 精确质量: 524.197266
• PSA: 121.28000
• LogP: 3.82900
• 外观性状: 白色至灰白色水晶般的固体
• 蒸汽压: 5.17E-19mmHg at 25°C
• 储存条件: 室温，干燥

生物活性

• 描述: Vardenafil盐酸盐是PDE5抑制剂。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 磷酸二酯酶(PDE)
  研究领域 >> 心血管疾病
• 参考文献:

  [1]. Saenz de Tejada, I., et al., The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res, 2001. 13(5): p. 282-90.

  [2]. Goldstein, I., et al., Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care, 2003. 26(3): p. 777-83.